Market Closed -
Euronext Paris
11:35:22 2024-05-31 am EDT
|
5-day change
|
1st Jan Change
|
2.41
EUR
|
-1.63%
|
|
-3.98%
|
-12.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
665.5
|
1,037
|
338.4
|
90.57
|
198.3
|
240.9
|
-
|
-
|
Enterprise Value (EV)
1 |
403.7
|
905.2
|
242.2
|
52.81
|
121.5
|
77.56
|
152.7
|
234
|
P/E ratio
|
-7.24
x
|
-15.4
x
|
-3.22
x
|
-0.9
x
|
-
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
32.2
x
|
15.1
x
|
5.57
x
|
3.7
x
|
23.1
x
|
7.86
x
|
4.82
x
|
2.05
x
|
EV / Revenue
|
19.5
x
|
13.2
x
|
3.99
x
|
2.16
x
|
14.2
x
|
2.53
x
|
3.05
x
|
1.99
x
|
EV / EBITDA
|
-3.87
x
|
-14.4
x
|
-2.17
x
|
-0.56
x
|
-1.65
x
|
-1.35
x
|
-2.62
x
|
-3.38
x
|
EV / FCF
|
-5.5
x
|
-8.66
x
|
-2.15
x
|
-0.63
x
|
-5.04
x
|
-1.05
x
|
-1.57
x
|
-2.22
x
|
FCF Yield
|
-18.2%
|
-11.6%
|
-46.4%
|
-159%
|
-19.8%
|
-95.6%
|
-63.6%
|
-45%
|
Price to Book
|
2.36
x
|
4.56
x
|
1.69
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
42,446
|
42,499
|
45,478
|
45,579
|
71,751
|
99,956
|
-
|
-
|
Reference price
2 |
15.68
|
24.40
|
7.440
|
1.987
|
2.764
|
2.410
|
2.410
|
2.410
|
Announcement Date
|
3/4/20
|
3/4/21
|
3/3/22
|
3/8/23
|
4/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.65
|
68.46
|
60.69
|
24.5
|
8.58
|
30.66
|
50.03
|
117.3
|
EBITDA
1 |
-104.3
|
-62.79
|
-111.4
|
-93.88
|
-73.52
|
-57.47
|
-58.3
|
-69.31
|
EBIT
1 |
-111
|
-70.94
|
-118.2
|
-104.9
|
-90.81
|
-69.39
|
-76.93
|
-41.63
|
Operating Margin
|
-537.42%
|
-103.62%
|
-194.83%
|
-428.31%
|
-1,058.44%
|
-226.34%
|
-153.78%
|
-35.48%
|
Earnings before Tax (EBT)
1 |
-103.5
|
-80.94
|
-113.2
|
-107.9
|
-100.9
|
-47.62
|
-72.65
|
-41.2
|
Net income
1 |
-91.7
|
-67.32
|
-103.3
|
-100.5
|
-94.32
|
-40.14
|
-69.72
|
-32.39
|
Net margin
|
-444.07%
|
-98.32%
|
-170.26%
|
-410.1%
|
-1,099.3%
|
-130.94%
|
-139.36%
|
-27.6%
|
EPS
|
-2.165
|
-1.586
|
-2.308
|
-2.205
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-73.36
|
-104.6
|
-112.5
|
-83.85
|
-24.1
|
-74.15
|
-97.1
|
-105.3
|
FCF margin
|
-355.25%
|
-152.75%
|
-185.31%
|
-342.31%
|
-280.85%
|
-241.88%
|
-194.08%
|
-89.74%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/4/20
|
3/4/21
|
3/3/22
|
3/8/23
|
4/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
12.36
|
3.68
|
2.703
|
1.968
|
16.44
|
3.234
|
1.828
|
1.531
|
1.857
|
5.974
|
3.001
|
6.874
|
14.89
|
44.89
|
8.316
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-22.77
|
-
|
-24.37
|
-7.787
|
19.69
|
-
|
-
|
EBIT
1 |
-27.98
|
-33.85
|
-33.31
|
-33.98
|
-7.92
|
-21.29
|
-21.61
|
-19.24
|
-27.61
|
-19.58
|
-23.25
|
-20.28
|
-12.24
|
6.453
|
-37.1
|
Operating Margin
|
-226.32%
|
-919.81%
|
-1,232.44%
|
-1,726.29%
|
-48.19%
|
-658.36%
|
-1,182.36%
|
-1,257.36%
|
-1,486.33%
|
-327.69%
|
-774.73%
|
-295.06%
|
-82.22%
|
14.37%
|
-446.12%
|
Earnings before Tax (EBT)
1 |
-25.41
|
-33.38
|
-19.02
|
-32.03
|
-26.95
|
-29.56
|
-12.41
|
-16.18
|
-39
|
5.429
|
-20.93
|
-16.82
|
-5.329
|
12.62
|
-30.93
|
Net income
1 |
-22.62
|
-30.64
|
-18.52
|
-29.17
|
-25.38
|
-27.33
|
-9.725
|
-16.28
|
-39.01
|
5.188
|
-20.93
|
-16.82
|
-5.329
|
12.62
|
-30.93
|
Net margin
|
-182.95%
|
-832.75%
|
-685.24%
|
-1,481.88%
|
-154.43%
|
-845.01%
|
-532.13%
|
-1,063.38%
|
-2,100.25%
|
86.84%
|
-697.35%
|
-244.65%
|
-35.78%
|
28.1%
|
-372%
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
5/12/22
|
8/4/22
|
11/3/22
|
3/8/23
|
5/4/23
|
8/3/23
|
11/6/23
|
4/29/24
|
5/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
262
|
132
|
96.2
|
37.8
|
76.8
|
163
|
88.2
|
6.86
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-73.4
|
-105
|
-112
|
-83.9
|
-24.1
|
-74.2
|
-97.1
|
-105
|
ROE (net income / shareholders' equity)
|
-28.2%
|
-27.5%
|
-45.2%
|
-62.6%
|
-92.7%
|
-8.77%
|
-8.42%
|
-17.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
6.630
|
5.350
|
4.400
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-1.460
|
-1.570
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
11.5
|
37.9
|
17.9
|
2.27
|
1
|
1.24
|
1.29
|
1.32
|
Capex / Sales
|
55.91%
|
55.42%
|
29.42%
|
9.26%
|
11.67%
|
4.06%
|
2.58%
|
1.12%
|
Announcement Date
|
3/4/20
|
3/4/21
|
3/3/22
|
3/8/23
|
4/29/24
|
-
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -12.81% | 261M | | +43.36% | 54.63B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|